摘要
Abstract
Objective:To evaluate the efficacy and safety of gefitinib combined with whole-brain radiotherapy(WBRT)in patients with epidermal growth factor receptor(EGFR)-mutant non-small cell lung cancer(NSCLC)with brain metastases.Method:Clinical data of 84 patients with EGFR-mutant NSCLC and brain metastases diagnosed at Shuyang Hospital of Traditional Chinese Medicine between January 2021 and December 2023 were retrospectively analyzed.According to treatment modality,patients were divided into a control group(gefitinib monotherapy)and a combination group(gefitinib plus WBRT),with 42 patients in each group.Intracranial objective response rate(iORR),intracranial disease control rate(iDCR),progression-free survival(PFS),overall survival(OS),and adverse events were compared between the two groups.Result:The iORR in the combination group was 71.4％,significantly higher than that in the control group(47.6％),and the iDCR was also higher in the combination group(P＜0.05).The median PFS was significantly longer in the combination group than in the control group(P＞0.05).The median OS was 20.2 months in the combination group and 16.4 months in the control group,with a statistically significant difference(P＜0.05).There was no significant difference in the incidence of grade ≥ 3 adverse events between the two groups.Conclusion:Gefitinib combined with WBRT can increase the intracranial response rate of patients with brain metastases of EGFR-mutated NSCLC,prolong PFS and OS,and its safety is controllable.It has a good clinical application prospect.关键词
EGFR突变/非小细胞肺癌/脑转移/EGFR-TKI/局部放疗生存分析Key words
Epidermal growth factor receptor-mutant/Non-small cell lung cancer/Brain metastases/Epidermal Growth Factor/Receptor Tyrosine Kinase Inhibitor/Local radiotherapy/Survival analysis
